Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2015

View Archived Issues

Urine-based prostate cancer diagnostic may help avoid unnecessary biopsies

Ferritin and IL-8 associated with clear cell renal carcinoma outcome

Bacteriolytic therapy feasible in advanced sarcoma patients

Malin plans to float on the ESM of Irish stock exchange to fund acquisitions and investments

FDA fast tracks AXS-02 for pain associated with complex regional pain syndrome

EMD Serono presents data from phase I study of MSC-2363318A

Ironwood Pharmaceuticals begins phase I study of IW-1973

TG Therapeutics and Checkpoint Therapeutics to develop immuno-oncology targeted antibodies

AOP Orphan completes enrollment in phase III trial of ropeginterferon alfa 2b

Phase III trial of VSV-EBOV for Ebola launching in Guinea

Eisai and Merck & Co. collaborate to study combination therapies in cancer

Baxter acquires SuppreMol

Tekmira completes merger with OnCore to create hepatitis B solutions company

FDA approves biosimilar product Zarxio

MAASTRO discloses dual action carbonic anhydrase inhibitors

Medshine Discovery patents DGAT-1 inhibitors

BioMmune reports in vivo progress in restoring immune recognition in cancer

U.S. scientists present novel and specific CYP26A1 inhibitors

Takeda reports development of lysophosphatidic acid receptor antagonists

Studies advance darunavir/cobicistat/emtricitabine/tenofovir alafenamide single tablet formulation

Merck & Co. describes new PAR-1 antagonists

FDA places hold on enrollment in ENDO trial of EndoBarrier

FDA approves Cresemba for invasive aspergillosis and invasive mucormycosis

Meiji Seika Pharma initiates phase III Japanese study of ziprasidone

Biogen Idec Japan launches long-acting agent for hemophilia A in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...